Prescription drug monitoring and dispensing of prescription opioids

Public Health Reports

Volumn 129, Issue 2, 2014, Pages 139-147

  Brady, Joanne E ^a   Wunsch, Hannah ^a   DiMaggio, Charles ^a   Lang, Barbara H ^a   Giglio, James ^a   Li, Guohua ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; PETHIDINE;

ANALGESIA; ARTICLE; DRUG MONITORING; ELECTRONIC PRESCRIBING; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HUMAN; PATIENT SAFETY; PRESCRIPTION; PRESCRIPTION DRUG MONITORING PROGRAM; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANALGESICS, OPIOID; DATABASES, FACTUAL; DRUG AND NARCOTIC CONTROL; DRUG MONITORING; DRUG OVERDOSE; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PRESCRIPTION DRUG DIVERSION; PRESCRIPTION DRUG MISUSE; PRESCRIPTION DRUGS; SEX DISTRIBUTION; SUBSTANCE-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 84894226022     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335491412900207     Document Type: Article

References (61)

1. National Institute on Drug Abuse (US). Topics in brief: prescription drug abuse. Bethesda (MD): NIDA; 2011. Also available from: URL: http://www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse [cited 2012 Sep 24].
2. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010;13:401-35.
3. Substance Abuse and Mental Health Services Administration (US). Results from the 2010 National Survey on Drug Use and Health: summary of national findings. Rockville (MD): SAMHSA; 2011. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Also available from: URL: http://www.samhsa.gov/data/nsduh/2k10nsduh/2k10results.htm#8.3 [cited 2013 Nov 1].
4. Emergency department visits involving nonmedical use of selected prescription drugs-United States, 2004-2008. MMWR Morb Mortal Wkly Rep 2010;59(23):705-9.
5. Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60(43):1487-92.
6. Substance Abuse and Mental Health Services Administration (US), Center for Behavioral Health Statistics and Quality. The DAWN report: highlights of the 2009 Drug Abuse Warning Network (DAWN) findings on drug-related emergency department visits. Rockville (MD): SAMHSA; 2010. Also available from: URL: http://www.oas.samhsa.gov/2k10/DAWN034/EDHighlights.htm [cited 2012 Apr 29].
7. White AM, Hingson RW, Pan IJ, Yi HY. Hospitalizations for alcohol and drug overdoses in young adults ages 18-24 in the United States, 1999-2008: results from the Nationwide Inpatient Sample. J Stud Alcohol Drugs 2011;72:774-86.
8. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures, United States, 2000-2009. JAMA 2012;307:1934-40.
9. Unintentional poisoning deaths-United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007;56(5):93-6.
10. Murphy SL, Xu J, Kochanek KD. Deaths: preliminary data for 2010. Natl Vital Stat Rep 2012 Jan 11;60:1-52.
11. Kochanek KD, Xu J, Murphy SL, Miniño AM. Deaths: preliminary data for 2009. Natl Vital Stat Rep 2011 Mar 16;59:1-51.
12. National Alliance for Model State Drug Laws. Model Prescription Monitoring Program (PDMP) Act. Santa Fe (NM): National Alliance for Model State Drug Laws; 2011.
13. Wilsey BL, Fishman SM, Gilson AM, Casamalhuppa C, Baxi H, Lin TC, et al. An analysis of the number of multiple prescribers for opioids utilizing data from the California Prescription Drug Monitoring Program. Pharmacoepidemiol Drug Saf 2011;20:1262-8.
14. Blumenschein K, Fink JL III, Freeman PR, James K, Kirsh KL, Steinke DT, et al.; Kentucky All Schedule Prescription Electronic Reporting Program (KASPER) Evaluation Team. Review of prescription drug monitoring programs in the United States. Lexington (KY): University of Kentucky, College of Pharmacy, Department of Pharmacy Practice and Science, Institute for Pharmaceutical Outcomes and Policy; 2010.
15. Simeone R, Holland L. An evaluation of prescription drug monitoring programs. Washington: Department of Justice (US), Office of Justice Programs; 2006.
16. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug moni-monitoring programs and death rates from drug overdose. Pain Med 2011;12:747-54.
17. Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv Res 2006;41(3 Pt 1):837-55.
18. Reifler LM, Droz D, Bailey JE, Schnoll SH, Fant R, Dart RC, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med 2012;13:434-42.
19. Li G, Brady JE, Lang BH, Giglio J, DiMaggio CJ. Characteristics of state prescription drug monitoring programs and drug overdose mortality. Poster presented at the 65th Annual Meeting of the American Society of Anesthesiologists; 2012 Oct 13-17; Washington.
20. Department of Justice (US), Drug Enforcement Administration. Automation of Reports and Consolidated Orders System (ARCOS) [cited 2012 Sep 6]. Available from: URL: http://www.deadiversion.usdoj.gov/arcos/index.html
21. H.R. 18583, 91st Cong., 2d Sess. (1970).
22. Department of Justice (US), Drug Enforcement Administration. ARCOS retail drug summary. Springfield (VA): Drug Enforcement Administration Office of Diversion Control; 2012.
23. Gammaitoni AR, Fine P, Alvarez N, McPherson ML, Bergmark S. Clinical application of opioid equianalgesic data. Clin J Pain 2003;19:286-97.
24. Brunton LL, Lazo JS, Parker KL. Goodman and Gilman's the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2005.
25. National Center for Health Statistics (US). CDC Wonder: bridged-race population estimates 1990-2009 request [cited 2011 Sep 6]. Available from: URL: http://wonder.cdc.gov/bridged-race-v2009.html
26. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008;299:70-8.
27. Green TC, Black R, Grimes Serrano JM, Budman SH, Butler SF. Typologies of prescription opioid use in a large sample of adults assessed for substance abuse treatment. PLoS One 2011;6:e27244.
28. Simoni-Wastila L, Ritter G, Strickler G. Gender and other factors associated with the nonmedical use of abusable prescription drugs. Subst Use Misuse 2004;39:1-23.
29. Whitmire JT, Adams GW. Unintentional overdose deaths in the North Carolina Medicaid population: prevalence, prescription drug use, and medical care services. SCHS Studies 2010;162:1-12. Also available from: URL: http://www.schs.state.nc.us/SCHS/pdf/SCHS_162_WEB_081310.pdf [cited 2012 Apr 20].
30. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief 2011;81:1-8.
31. Census Bureau (US). Census Bureau regions and divisions with state FIPS codes [cited 2013 Nov 1]. Available from: URL: http://www.census.gov/geo/maps-data/maps/docs/reg_div.txt
32. Department of Justice (US), Drug Enforcement Administration. State prescription drug monitoring programs [cited 2008 Dec 19]. Available from: URL: http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm
33. Ballinger GA. Using generalized estimating equations for longitudinal data analysis. Org Res Methods 2004;7:127-50.
34. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
35. Cui J. QIC program and model selection in GEE analyses. Stata J 2007;7:209-20.
36. SAS Institute, Inc. SAS®: Version 9.2. Cary (NC): SAS Institute, Inc.; 2009.
37. StataCorp LP. Stata®: Version 11.2. College Station (TX): StataCorp LP; 2011.
38. Ball J, Lehder Roberts D. The DAWN report: oxycodone, hydrocodone, and polydrug use, 2002. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2004. Also available from: URL: http://www.samhsa.gov/data/2k4/oxycodone/oxycodone.pdf [cited 2013 Jan 22].
39. MITRE Corporation. Enhancing access to prescription drug monitoring programs using health information technology: work group recommendations. McLean (VA): MITRE Corporation; 2012. Also available from: URL: http://www.healthit.gov/sites/default/files/work_group_document_integrated_paper_final.pdf [cited 2013 Jul 2].
40. Department of Justice (US), Bureau of Justice Assistance. Interstate data sharing becomes a reality for prescription drug monitoring programs. Washington: Department of Justice, Bureau of Justice Assistance; 2012. Also available from: URL: https://www.bja.gov/JusticeToday/PMIX.pdf [cited 2013 Jan 22].
41. Alliance of States with Prescription Monitoring Programs. Frequently asked questions: the PMIX national architecture [cited 2012 Nov 1]. Available from: URL: http://www.pmpalliance.org/pdf/PMIX%20ARCH%20FAQ_FINAL.pdf
42. Manchikanti L. National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 2007;10:399-424.
43. McLellan AT, Turner B. Prescription opioids, overdose deaths, and physician responsibility. JAMA 2008;300:2672-3.
44. Volkow ND, McLellan TA. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011;305:1346-7.
45. Dormuth CR, Miller TA, Huang A, Mamdani MM, Juurlink DN. Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines. CMAJ 2012;184:E852-6.
46. Clark T, Eadie J, Kreiner P, Strickler G. Prescription drug monitoring programs: an assessment of the evidence for best practices. Washington: The Pew Charitable Trusts; 2012. Also available from: URL: http://www.pewhealth.org/reports-analysis/reports/prescription-drug-monitoring-programs-an-assessment-of-the-evidence-for-best-practices-85899418404 [cited 2013 Jan 22].
47. Ulbrich TR, Dula CA, Green CG, Porter K, Bennett MS. Factors influencing community pharmacists' enrollment in a state prescription monitoring program. J Am Pharm Assoc 2010;50:588-94.
48. Prescription Monitoring Program Center for Excellence. Best practices for prescription monitoring programs. Waltham (MA): Prescription Monitoring Program Center for Excellence, Brandeis University; 2012. Also available from: URL: http://www.pmpexcellence.org/sites/all/pdfs/COE_BriefingOnBestPractices_final_april_2012.pdf [cited 2012 Sep 19].
49. Perrone J, Nelson LS. Medication reconciliation for controlled substances-an "ideal" prescription-drug monitoring program. N Engl J Med 2012;366:2341-3.
50. Prescription Drug Abuse and Health Information Technology Work Group. Action plan for improving access to prescription drug monitoring programs through health information technology. Washington: Department of Health and Human Services (US); 2011. Also available from: URL: http://www.healthit.gov/sites/default/files/rules-regulation/063012-final-action-plan-clearance.pdf [cited 2013 Oct 31].
51. Katz N, Houle B, Fernandez KC, Kreiner P, Thomas CP, Kim M, et al. Update on prescription monitoring in clinical practice: a survey study of prescription monitoring program administrators. Pain Med 2008;9:587-94.
52. Finklea KM, Bagalman E, Sacco LN. Prescription drug monitoring programs. Washington: Congressional Research Service; 2012. Also available from: URL: http://www.hsdl.org/?view&did=716793 [cited 2012 Sep 19].
53. Katz N, Panas L, Kim M, Audet AD, Bilansky A, Eadie J, et al. Usefulness of prescription monitoring programs for surveillance-analysis of schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiol Drug Saf 2010;19:115-23.
54. Gilson AM, Fishman SM, Wilsey BL, Casamalhuapa C, Baxi H. Time series analysis of California's prescription monitoring program: impact on prescribing and multiple provider episodes. J Pain 2012;13:103-11.
55. Lambert D. Impact evaluation of Maine's prescription drug monitoring program. Portland (ME): University of Southern Maine, Muskie School of Public Service; 2007. Also available from: URL: http://muskie.usm.maine.edu/Publications/ihp/PrescDrugMonitoring PgrmExecSum.pdf [cited 2012 Sep 19].
56. Baehren DF, Marco CA, Droz DE, Sinha S, Callan EM, Akpunonu P. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med 2010;56:19-23.
57. Farberov S. "They're like a swarm of locusts:" authorities struggling to crack down on "painkiller tourists" who flood states with illegal prescription drugs. The Daily Mail 2012 Jul 8. Also available from: URL: http://www.dailymail.co.uk/news/article-2170742/Authorities-struggling-crack-painkiller-tourists-illegal-prescription-drugs.html [cited 2012 Aug 4].
58. CDC grand rounds: prescription drug overdoses-a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012;61(01):10-3.
59. Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61(06):101-5.
60. Lazar K. Blue Cross plan targets abuse of painkillers. The Boston Globe 2012 May 7.
61. Sherrod Brown Senator for Ohio. Sen. Brown announces plan to combat prescription drug abuse by targeting doctor-shopping and pharmacy-hopping [press release] 2013 May 18 [cited 2013 Jul 2]. Available from: URL: http://www.brown.senate.gov/rxtakeback